http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104558162-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-815 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-04 |
| filingDate | 2013-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104558162-B |
| titleOfInvention | The solid phase synthesis process of Angiomax intermediate |
| abstract | The invention discloses the solid phase synthesis process of Angiomax intermediate.The present invention provides the solid phase synthesis process of peptide resin 18：Step 1, in aprotic polar solvent, organic base is subjected to reacting for removing proline fluorenes methoxy carbonyl acyl group amino protecting group with peptide resin 17, obtains peptide resin 17 '；Step 2, in aprotic polar solvent, under the conditions of condensing agent and catalyst are existing, by peptide resin 17 ' and Fmoc-Arg (R obtained in step 1 2 )-OH progress condensation reactions, obtain peptide resin 18；The aprotic polar solvent is the mixed solvent of N,N-dimethylformamide and dichloromethane.The solid phase synthesis process of the present invention can promote amino acid Fmoc-Arg (Pbf)-OH of big steric hindrance to smoothly complete condensation reaction, simple for process, reaction condition is mild, high conversion rate, condensation rate reach that 84%~100%, production cost is low, is suitable for large-scale industrial production. |
| priorityDate | 2013-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 88.